Get Smarter on Biotech in 5 Minutes a Day.
Focused insights — expertly curated, clearly delivered, ready for action.
Get the Daily Brief
What’s in Today’s Brief? (March 14th Preview)
-
Immutep’s phase III shock: efti trial stopped for futility
Immutep’s Phase III TACTI-004 trial of eftilagimod alfa (efti) in first-line non‑small‑cell lung cancer was halted after an independent data monitoring committee recommended stopping for futility. The sponsor disclosed the decision following an interim analysis, prompting a dramatic market reaction and an immediate program reassessment. The readout contrasts with prior positive signals for efti in earlier cohorts and leaves the company poring over datasets to identify drivers of the failure. Immutep CEO Marc Voigt said the team is “disappointed and surprised” and will undertake a comprehensive review to decide next steps. Investors have already repriced the company, underscoring execution and late‑stage risk in immuno‑oncology development.
-
Ultragenyx gene therapy clears major Phase 3 endpoint in OTC deficiency
Ultragenyx reported that its gene therapy candidate met a key primary endpoint in a Phase 3 trial for ornithine transcarbamylase (OTC) deficiency, a rare urea cycle disorder. The company disclosed the result from the 37‑patient study, marking a pivotal clinical milestone for a monoallelic metabolic condition with high unmet need. The result strengthens Ultragenyx’s late‑stage portfolio in rare metabolic diseases and positions the program for regulatory discussions. The data will determine next regulatory and commercialization strategy, including filing timing and potential labeling scope. Investors and partners will watch safety, durability, and the second primary endpoint readout closely before projecting commercial impact.
-
Lantheus wins tentative FDA ANDA for Lutathera rival amid patent war
The FDA issued tentative approval for Lantheus’ ANDA for PNT2003, an asserted generic equivalent to Novartis’ radioligand Lutathera (lutetium Lu 177 dotatate), even as Novartis pursues multiple patent infringement suits. The tentative approval recognizes bioequivalence but cannot convert to final approval while litigation over formulation and process patents proceeds. This regulatory move could pressure Lutathera’s pricing and supply if Lantheus ultimately clears legal hurdles, and it spotlights the unique IP complexity of radiopharmaceuticals, where formulation and process patents often protect marketed products. The case has drawn judicial commentary about its unusual scope and dispute density, highlighting litigation risk as a barrier to generic radiopharmaceutical entry.
-
GSK wins expanded FDA clearance for RSV vaccine Arexvy
GSK secured broader FDA clearance for its respiratory syncytial virus (RSV) vaccine Arexvy, expanding approved indications and potentially boosting uptake after an initially sluggish launch. The agency action follows additional data submissions and signals regulatory receptivity to new preventive options for older adults. The expanded label could accelerate vaccination campaigns in target populations and generate renewed commercial momentum for GSK’s vaccine franchise. Market access and uptake will hinge on payer coverage, public health recommendations, and comparative positioning versus other RSV products.
-
China approves first commercial brain‑computer implant for spinal injuries
China granted commercial approval to Neuracle Medical Technology’s invasive brain‑computer interface (BCI) for people with spinal cord injuries, the first national clearance worldwide for a BCI device intended for regular clinical use. The coin‑sized wireless implant records cortical signals and decodes them to control external devices, aiming to restore function for patients with paralysis. Regulatory approval in China sets a precedent for commercial BCI deployment and may accelerate clinical adoption and investment in neural interface startups. The decision contrasts with more cautious regulatory paths in the U.S. and Europe, and will intensify scrutiny of safety, long‑term reliability, and post‑market surveillance.
...and 5 more selected Biotech stories in today’s full edition — or archive.
Why BioBriefs?
- Expertly curated. We scan 200+ sources daily to deliver only what matters.
- Smart context. Each brief explains why it matters and who it impacts.
- Made for pros. Trusted by founders, scientists, investors, and strategists.
Who Reads BioBriefs?
- Biotech founders & execs
- R&D and Clinical leads
- Life sciences investors
- Regulators and BD pros
- Translational scientists and tech scouts
Stay sharp. Be first to what’s next.
About BioBriefs
We’re a team of biotech analysts, technical writers, and founders who know what it’s like to scan 40 tabs and still miss what matters. BioBriefs was built to solve that. We track the signals, condense the insights, and get them to you before your day starts.